Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

[1]  A. Montero,et al.  HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients , 2022, Journal of the National Comprehensive Cancer Network.

[2]  A. Madabhushi,et al.  Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. , 2021, European Journal of Cancer.

[3]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[4]  L. Fan,et al.  Risk and prognostic factors of breast cancer with liver metastases , 2020, BMC Cancer.

[5]  A. Madabhushi,et al.  Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study. , 2020, Lung cancer.

[6]  A. Madabhushi,et al.  Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. , 2019, Lung cancer.

[7]  R. Bale,et al.  Local Treatment of Breast Cancer Liver Metastasis , 2019, Cancers.

[8]  E. Quaquarini,et al.  The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments , 2019, Cancers.

[9]  M. Benelli,et al.  Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice , 2019, Front. Oncol..

[10]  Prateek Prasanna,et al.  Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer , 2019, JAMA network open.

[11]  J. Abraham,et al.  Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy , 2019, Breast Cancer Research and Treatment.

[12]  A. Madabhushi,et al.  Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma. , 2019, Radiology. Artificial intelligence.

[13]  H. Iwata,et al.  MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.

[14]  K. Gelmon,et al.  Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up , 2019, Breast Cancer Research and Treatment.

[15]  Marcus Schmidt,et al.  Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer , 2018, Therapeutic advances in medical oncology.

[16]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Criscitiello,et al.  CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion , 2018, ESMO Open.

[18]  E. Winer,et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Claude B Sirlin,et al.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. , 2018, The British journal of radiology.

[20]  J. Erler,et al.  Hypoxic Signalling in Tumour Stroma , 2018, Front. Oncol..

[21]  M. Ellis,et al.  CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.

[22]  A. Madabhushi,et al.  Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI , 2017, Breast Cancer Research.

[23]  A. Tutt,et al.  3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Ming Chen,et al.  Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT , 2016, Translational oncology.

[25]  Milan Sonka,et al.  3D Slicer as an image computing platform for the Quantitative Imaging Network. , 2012, Magnetic resonance imaging.

[26]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[27]  H. Bismuth,et al.  Is Liver Resection Justified for Patients With Hepatic Metastases From Breast Cancer? , 2006, Annals of surgery.

[28]  L. Coignet,et al.  NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype , 2006, Oncogene.

[29]  O. Matsui,et al.  Peritumoral Rim Enhancement of Liver Metastasis: Hemodynamics Observed on Single-Level Dynamic CT During Hepatic Arteriography and Histopathologic Correlation , 2002, Journal of computer assisted tomography.

[30]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[31]  OUP accepted manuscript , 2022, The Oncologist.